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ABSTRACT 
 
In this work, an untargeted metabolomic approach based on sensitive analysis by on-
line solid-phase extraction capillary electrophoresis mass spectrometry (SPE-CE-MS) in 
combination with multivariate data analysis is proposed as an efficient method for the 
identification of biomarkers of Huntington’s disease (HD) progression in plasma. For 
this purpose, plasma samples from wild type (wt) and HD (R6/1) mice of different ages 
(8, 12 and 30 weeks), were analysed by C18-SPE-CE-MS in order to obtain the 
characteristic electrophoretic profiles of low molecular mass compounds. Then, 
multivariate curve resolution alternating least squares (MCR-ALS) was applied to the 
multiple full scan MS data sets. This strategy permitted the resolution of a large number 
of metabolites being characterised by their electrophoretic peaks and their 
corresponding mass spectra. A total number of 29 compounds were relevant to 
discriminate between wt and HD plasma samples, as well as to follow-up the HD 
progression. The intracellular signalling was found to be the most affected metabolic 
pathway in HD mice after 12 weeks of birth, when mice already showed motor 
coordination deficiencies and cognitive decline. This fact agreed with the atrophy and 
dysfunction of specific neurons, loss of several types of receptors and changed 
expression of neurotransmitters. 
 
 
 
 
 
 
 
1. Introduction 
 
Huntington’s disease (HD) is an inherited neurodegenerative disorder, which is 
characterised by progressive motor and cognitive disturbances. HD is caused by an 
expansion of the cytosine-adenine-guanine (CAG) repeat in the exon 1 of the hungtintin 
gene (HTT), which encodes a stretch of glutamines in the hungtintin protein [1–8]. 
Although the HTT gene is ubiquitously expressed as the huntingtin protein in most 
tissues, HD pathology has primarily been located to the basal ganglia and to the 
neocortex. The pathology involves atrophy and dysfunction of specific neurons, loss of 
several types of receptors, changed expression of neurotransmitters and key proteins, as 
well as formation of ubiquitin positive aggregates [1–8]. HD is a fatal disease, and the 
median interval between clinical diagnosis and death is typically given as 15 to 20 years 
[2,4,6,8].                                               
 
By use of predictive genetic testing, it is possible to identify individuals who carry the 
HTT gene defect before the onset of symptoms, providing a unique window of 
opportunity for intervention aimed at preventing or delaying disease onset [4,7]. 
However, without robust and practical measures of disease progression, the efficacy of 
therapeutic interventions in this premanifest HD cannot be readily assessed. 
Neuroimaging and biochemical biomarkers are being investigated for their potential in 
clinical use and their value in the development of future treatments [4,7]. Modern 
neuroimaging techniques such as magnetic resonance imaging (MRI) enable high- 
quality images of brain structure and function to be obtained [9,10]. However, 
metabolites that can be quantified in biofluids, such as blood or urine, are appealing due 
to the improved selectivity, the minimal requirement for patient involvement, 
opportunity for rapid bulk processing of specimens, availability of reliable assays and 
possibility of carrying out multiple analyses on a single sample [5,7,11]. 
 
Metabolomics aims to obtain a comprehensive coverage of low molecular mass 
compounds from biological systems [12–14]. Metabolomics studies can be approached 
using targeted or untargeted analysis [15–17]. In targeted analysis, a specified list of 
metabolites is analysed. In contrast, untargeted analysis requires comprehensive 
metabolite measurements. Furthermore, it can implicate previously unrecognised 
metabolites or pathways with a unique phenotype and, therefore, is a powerful platform 
to elucidate novel biomarkers and gain insight into disease pathogenesis.  
 
Different techniques are currently used for untargeted metabolomics, including nuclear 
magnetic resonance (NMR), gas chromatography mass spectrometry (GC-MS), liquid 
chromatography mass spectrometry (LC-MS) and capillary electrophoresis mass 
spectrometry (CE-MS) [17–21]. For the first time to our knowledge, the use of on-line 
C18 solid-phase extraction capillary electrophoresis mass spectrometry (C18-SPE-CE-
MS) is proposed as an alternative sensitive method for metabolomic studies of 
biological fluids, which are complex diluted samples. CE is a versatile, high-
performance separation technique with many desirable characteristics such as 
instrumental simplicity, full automation, high efficiency, low consumption of sample 
and reagents and reduced analysis times. However, like many other microanalytical 
techniques, it has poor concentration sensitivity for most analytes, from low molecular 
mass compounds to biopolymers such as proteins [22,23]. Several strategies have been 
proposed to improve CE sensitivity. Today, SPE-CE is becoming widely recognised as 
a powerful approach that overcomes this major drawback [22–27]. In SPE-CE, a 
microcartridge placed inside and near the inlet of the separation capillary contains an 
appropriate extraction sorbent (in our case, C18). This sorbent selectively retains the 
target analyte, enabling large volumes of sample to be introduced (50-100 μL). The 
retained analyte is eluted in a small volume of an appropriate solution (25-50 nL), 
which results in sample clean-up and concentration enhancement with minimum sample 
handling before separation and detection, for example, by on-line mass spectrometry 
(SPE-CE-MS) [22–27].  
 
Chemometric methods play a crucial role in data processing, exploration and 
classification of the massive data sets generated in metabolomic studies [28–34].  If the 
goal of the study is the compound detection, the use of resolution methods such as 
multivariate curve resolution alternating least squares (MCR-ALS) can be an excellent 
alternative. MCR-ALS can resolve overlapped electrophoretic/chromatographic peaks 
from the collected data and provide the separation profiles and mass spectra of the 
constituents in the analysed samples. This approach allows overcoming problems such 
as retention time shifts, background noise contributions, and differences in signal-to-
noise (S/N) ratios among different injections. Several published articles focus on the 
application of MCR-ALS to solve similar problems in LC-MS [32,33] and GC-MS [34]; 
but only a few studies have been previously reported combining CE-MS and MCR-ALS 
in metabolomic applications [35]. 
 
In this paper, we evaluate the capacity of SPE-CE-MS combined with advanced 
multivariate data analysis to preconcentrate, separate, detect and identify low molecular 
mass metabolites in plasma samples from wild type (wt) and HD (R6/1) mice of 
different ages (8, 12 and 30 weeks). A comparison between the different untargeted 
metabolomic profiles allows us to propose novel potential biomarker candidates 
involved in the progression of Huntington’s disease, which could be useful for 
prediction of disease onset or response to treatment. 
 
2. Materials and methods 
2.1 Chemicals and reagents 
 
All the chemicals used in the preparation of buffers and solutions were of analytical 
reagent grade. Acetonitrile (99.9%), methanol (99.9%), 2-propanol (≥99.9%), formic 
acid (HFor) (99.0%), glacial acetic acid (HAc), ammonia (25%) and sodium hydroxide 
(≥99.0%, pellets) were purchased from Merck (Darmstadt, Germany). Methionine 
enkephalin (Met, ≥97.0%) and endomorphin 1 (End 1, ≥98.0%) were provided by 
Sigma (St. Louis, MO, USA). Dynorphin A (1-7) (Dyn A, ≥98.0%) was supplied by 
Bachem (Bubendorff, Switzerland). Polyethylene glycol (PEG) 8,000 Mr (~50% in 
water) was purchased from Fluka (Buchs, Switzerland). Water with a conductivity value 
lower than 0.05 µS/cm was obtained using a Milli-Q water purification system 
(Millipore, Molsheim, France). 
2.2 Electrolyte solutions, sheath liquid and standard solutions 
 
Aqueous standard solutions (2500 µg·mL-1) of Dyn A, End 1 and Met peptides were 
prepared and stored in a freezer at -20ºC when not in use. A 10 ng·mL-1 standard 
mixture of the three peptides was prepared and analysed at the beginning and at the end 
of each SPE-CE-MS sequence, in order to check the proper functioning of the on-line 
SPE microcartridges. The background electrolyte (BGE) contained 50 mM of HAc and 
50 mM of HFor and was adjusted to pH 3.50 with ammonia. The sheath liquid solution 
consisted of a hydroorganic mixture of 60:40 v/v 2-propanol:water with 0.05% v/v of 
HFor. All solutions were passed through a 0.45 µm nylon filter (MSI, Westboro, MA, 
USA) before analysis and were stored at 4ºC when not in use. The sheath liquid was 
degassed for 10 min by sonication before use.  
 
2.3 Mice blood plasma and sample preparation 
 
Plasma samples from male wild type mice (wt) and R6/1 transgenic mice (B6CBA 
background) expressing exon 1 of mutant huntingtin with 145 repeats (HD, R6/1) of 
different ages (8, 12 and 30 weeks, early, middle and late disease stage, respectively), 
were kindly supplied by the Department of Cellular Biology, Immunology and 
Neurosciences (Faculty of Medicine, University of Barcelona) [36]. Blood from mice 
was collected by cardiac puncture in standard clinical vials and placed on ice. Plasma 
was separated from the blood cells, pooled, deposited into polyethylene tubes and 
frozen at -20°C. It is worth mentioning that due to the small amount of blood that was 
possible to extract from a single mouse (between 1 and 2 mL), each set of samples 
corresponded to the combination of the plasma obtained from 4 or 5 mice. All animal 
procedures were approved by the CEEA committee of the University of Barcelona and 
were in accordance with the European Communities Council Directive (2010/63/EU). 
 
The sample pretreatment used for the analysis of low molecular mass compounds in 
plasma samples was described elsewhere [22,37]. The off-line double step pretreatment 
of plasma samples consisted of protein precipitation with cold acetonitrile 
(plasma:acetonitrile, 200 µL:1200 µL) followed by centrifugal filtration with 10000 Mr 
cut-off cellulose acetate filters (Amicon® Ultra-0.5, Millipore). Centrifugal filters were 
passivated before the first use with 5% v/v of PEG in water [37].  
 
2.4 Apparatus and procedures 
 
pH measurements were made with a Crison 2002 potentiometer and a Crison electrode 
52-03 (Crison Instruments, Barcelona, Spain). Centrifugal filtration was carried out in a 
cooled Rotanta 460 centrifuge (Hettich Zentrifugen, Tuttlingen, Germany) for 
centrifugation at controlled temperature (25ºC). 
 
2.4.1 On-line solid-phase extraction capillary electrophoresis mass spectrometry 
 
The construction of the microcartridge or analyte concentrator for C18-SPE-CE-MS was 
carried out as described elsewhere [22,37]. All fused silica capillaries were supplied by 
Polymicro Technologies (Phoenix, AZ, USA). The microcartridge (7 mm LT x 250 µm 
id x 360 µm od) was inserted inside the separation capillary (72 cm LT x 75 µm id x 360 
µm od), at 7.5 cm from the inlet, using two plastic sleeves. Previously, it was filled with 
the sorbent found in C18 Sep-pak cartridges (Waters, Milford, MA, USA). The sorbent 
particles were retained in the microcartridge between two frits (0.1 cm). 
 
All capillary rinses were performed at high pressure (930 mbar). New separation 
capillaries were flushed with 1.0 M NaOH (20 min) and water (15 min) before inserting 
the microcartridge. This activation procedure was performed off-line to avoid the 
unnecessary entrance of NaOH into the MS system. Once inserted the microcartridge, 
the SPE-CE-MS capillaries were first conditioned by consecutive flushes of water (1 
min), methanol (1 min), water (1 min) and BGE (3 min) at 930 mbar. Standard peptide 
mixture (Dyn A, End 1 and Met) or mice plasma samples were then introduced at 930 
mbar for 10 min (approximately 60 µL using the Hagen-Poiseuille equation [38]). A 
final rinse with the BGE (2 min at 930 mbar) eliminated non-retained molecules and 
equilibrated the capillary before the elution. Retained compounds were eluted by 
injecting a solution of 60:40 v/v methanol:water with 50 mM HAc and 50 mM HFor at 
50 mbar for 10 s (approximately 50 nL [38]). Separation was carried out at 25ºC by 
applying a voltage of 17 kV (normal polarity, cathode in the outlet). Between runs, the 
capillary was rinsed for 2 min with water and 2 min with acetonitrile, in order to avoid 
carry-over between consecutive analyses. In general, the different plasma samples (i.e. 
8wt, 12wt, 30wt and 8HD, 12HD and 30HD) were analysed in triplicate (with the 
exception of 12wt, 12HD and 30HD, for which only two replicates were analysed due 
to the small volume of plasma sample available). Each series of replicate analyses was 
performed in a new SPE-CE-MS capillary due to the limited durability of the SPE 
microcartridges (10 analyses) because of the complexity of the plasma matrix and the 
limited selectivity of the C18 sorbent. After these analyses, the extraction efficiency 
decreased and the microcartridge was packed until it was completely clogged [39]. At 
the beginning and at the end of each sequence, a 10 ng·mL-1 standard peptide mixture 
was analysed as a quality control of the system. 
 
All CE-MS experiments were performed in an HP3D CE system coupled with an 
orthogonal G1603A sheath-flow interface to a 6220 oa-TOF LC/MS spectrometer 
(Agilent Technologies, Waldbronn, Germany). The sheath liquid was delivered at a 
flow rate of 3.3 µL·min-1 by a KD Scientific 100 series infusion pump (Holliston, MA, 
USA). ChemStation C.01.06 software (Agilent Technologies) was used for CE control 
and separation data acquisition (e.g. voltage, temperature and current), and was run in 
combination with MassHunter B.04.00 workstation software (Agilent Technologies) for 
control of the mass spectrometer and MS data acquisition. 
 
The TOF mass spectrometer was operated under optimum conditions in positive mode 
using the following parameters: capillary voltage 4000 V, drying gas temperature 
200ºC, drying gas flow rate 4 L·min-1, nebulizer gas 7 psig, fragmentor voltage 215 V, 
skimmer voltage 60 V, OCT 1 RF Vpp voltage 300 V. Data were collected in profile at 
1 spectrum/s between 40 and 1250 m/z, with the mass range set to high resolution mode 
(4 GHz). A standard tune and an external mass calibration were performed daily at the 
beginning of the day following the manufacturer instructions using the typical LC-MS 
sprayer and ESI-L tuning mix (Agilent Technologies). 
 
2.5 Data analysis 
 
SPE-CE-MS data was analysed by a combination of advanced chemometric tools to 
evaluate the most significant metabolic changes involved in HD. Figure 1 shows a 
summary of the data analysis workflow, which is explained in detail in this section. 
 
2.5.1. Data pre-processing of data set 
 
First, SPE-CE-MS raw data was converted to .txt format by using the ProteoWizard 
software [40] and, then, imported into the MATLAB environment (The Mathworks Inc. 
Natick, MA, USA) using in-house made routines. During this import process, MS 
information was compressed to 0.01 Da/e resolution. Every sample provided a data 
matrix with 2490 rows (migration times, 40 minutes of electrophoretic run) and 121001 
columns (m/z values, from 40 to 1250) (see Figure 1A). An automatic weighted least 
squares baseline correction was applied before to the MCR-ALS analysis. 
 
2.5.2. Full scan MS data arrangement and MCR-ALS analysis 
 
MCR-ALS is a chemometric method especially useful to analyse multicomponent 
systems with strongly overlapping contributions, such as those present in CE 
separations, where the electrophoretic behaviour of metabolites is rather similar [41]. In 
the case of SPE-CE-MS, full scan MS data matrix D contains the experimental mass 
spectra at all retention times in their rows and the electropherograms at all m/z values in 
their columns. MCR-ALS analysis of the data matrix D, following a bilinear model, 
gives two factor matrices, C and ST, as in Eq. 1:  
𝐃 =  𝐂𝐒𝐓  + 𝐄         (1)         
where matrix C contains the electrophoretic profiles of the resolved contributions 
(components), matrix ST contains the corresponding mass spectra of the resolved 
contributions, and matrix E contains the residuals unexplained by the model.  
 
The different samples can be simultaneously analysed and compared by MCR-ALS 
using a column-wise augmented data matrix configuration (see matrix Daug in Eq. 2 and 
Figure 1B), following the strategy described in the work of Ortiz-Villanueva [35]:  
𝐃𝐚𝐮𝐠  =  [
𝑫𝟏
⫶
𝑫𝟏𝟓
] =  [
𝑪𝟏
⫶
𝑪𝟏𝟓
] 𝐒𝐓 +  [
𝑬𝟏
⫶
𝑬𝟏𝟓
]  =  𝐂𝐚𝐮𝐠𝐒
𝐓 +  𝐄𝐚𝐮𝐠    (2) 
This approach allowed obtaining a common matrix of the mass spectra of the resolved 
components (ST) for all samples, and a set of matrices describing the resolved 
electrophoretic profiles (Caug) in every sample. These electrophoretic peaks resolved in 
matrix Caug are allowed to vary in position (shifts) and shape among samples because 
the only requirement for a proper resolution is that the resolved spectra are the same for 
the common constituents in the different samples [42]. This aspect is especially useful 
in the case of CE data where migration shifts among samples occur and, hence, the 
alignment of electrophoretic peaks before analysis is not needed. 
 
In this study, the electropherograms were partitioned in two time windows 
corresponding to the two regions with the most intense peaks (selected regions, 
depending on the sample, varied approximately from 10 to 25 min and from 30 to 40 
min, respectively, Figure 2). Then, the resulting data matrices were further reduced in 
their m/z mode dimension in 30 different m/z ranges (m/z widths for reduction were 20, 
50 and 100 m/z in the m/z ranges from 40-400, 400-800 and 800-1250 m/z, 
respectively) (Figure 1B) [35].  
 
MCR-ALS analysis was carried out following standard procedures for the determination 
of the number of components (SVD, [43]) and initial estimates (SIMPLISMA, [44]). 
ALS optimization was performed under non-negativity constraints for electrophoretic 
(Caug) and spectral (ST) profiles, and spectral normalization (equal height) [45,46]. 
2.5.3. Detection and identification of potential metabolites 
 
For every resolved MCR-ALS component, electropherogram (peak) profiles of the six 
sample sets (i.e. 8wt, 12wt, 30wt and 8HD, 12HD and 30HD) were compared. Only 
resolved components of Caug that showed S/N ratios higher than 10% of the abundance 
of the most intense component were selected. Next, their corresponding mass spectra 
profiles (ST) were used to identify the m/z values causing the differentiation between wt 
and HD plasma samples at 8, 12 and 30 weeks. Finally, peak areas of these candidate 
m/z values were recovered from the full scan SPE-CE-MS data using the MassHunter 
workstation software, taking as a reference the m/z value and the migration time of the 
MCR-ALS resolved components (Figure 1C). Areas were finally normalised 
considering the peak area corresponding to a compound present in all the samples that 
was not discriminant between control and HD samples (m/z of 72.9858, in the first time 
window). 
 
These areas were used to build a data matrix containing the area of each candidate 
(feature) in every sample. This data matrix was autoscaled in order to give equal 
weighting to all candidates in the measured samples. Finally, partial least squares 
discriminant analysis (PLS-DA) models were applied to the autoscaled data matrix to 
evaluate sample discrimination and to identify the most important features. There are 
numerous methods for feature selection when considering PLS models. In this work, the 
variable importance in the projection (VIP) method was used [47], because it is one of 
the preferred methods to deal with metabolomic data due to its ability for handling 
multicollinear data [48]. For each model, VIP scores estimate the importance of each 
feature in the projection. Only features with a VIP score over a particular threshold 
(usually VIP=1) are considered important and selected for further analysis. In all the 
cases, leave-one-out cross-validation was used to assess the performance of the built 
models. Thereafter, the accurate experimental molecular mass values of the finally VIP 
selected metabolites were searched in on-line databases resources, such as METLIN 
Metabolite Database [49] and Human Metabolome Database (HMDB) [50]. A small 
error from the calculated (theoretical) molecular mass (Mr) was used to evaluate the 
accuracy of possible molecular formulas (Er≤20 ppm, │Mr experimental - Mr theoretical │ / Mr 
theoretical * 10
6). Finally, the list of the tentatively identified metabolites was used to 
investigate the possible metabolic pathways and mechanisms involved in HD according 
to the KEGG database [51] (Figure 1C).  
 
2.5.4. Software 
 
Most of the calculations and data analysis were performed under MATLAB R2013a 
(The MathworksInc. Natick, MA, USA). PLS Toolbox 7.3.1 (Eigenvector Research 
Inc., Wenatchee, WA, USA) was used for PLS-DA and VIP calculations; and MCR-
ALS toolbox [42] was used for resolution of electrophoretic and mass spectral 
metabolite profiles from full MS scan augmented data matrices.  
 
3. Results and discussion 
3.1 Analysis of mice plasma by C18-SPE-CE-MS 
 
Untargeted metabolomics analysis requires a comprehensive coverage of low molecular 
mass compounds from biological samples. However, very often sample amount 
limitations, matrix complexity and metabolite concentration preclude direct analysis 
with CE-MS. With the aim of solving these issues, plasma samples from wt (control) 
and HD mice were analysed by C18-SPE-CE-MS in order to preconcentrate, separate, 
detect and identify low molecular mass compounds and establish significant differences 
between the global metabolite profiles from different groups of samples. In order to 
evaluate HD progression in individuals at the premanifest motor stage of the disease, 
plasma samples from wt and HD mice were analysed at 8, 12 and 30 weeks of age. In 
HD mice, these samples corresponded to early (asymptomatic), middle (symptomatic) 
and late (terminal) disease stage mice, respectively, although this classification is only 
based on motor coordination deficiencies [52].  
  
The applied C18-SPE-CE-MS method in positive ESI mode was developed for the 
analysis of peptides in human plasma in previous works [22,37], but preliminary 
experiments showed that it was also useful to obtain a rich fingerprint of low molecular 
mass compounds in mouse plasma. As shown in those studies, all the plasma samples 
were subjected to an off-line sample pretreatment before C18-SPE-CE-MS in order to 
prevent microcartridge saturation due to the limited selectivity of the C18 sorbent. A 
double step pretreatment based on solvent precipitation and centrifugal filtration with 
Mr cut-off filters was applied to eliminate salts and high molecular mass compounds 
(i.e. proteins). This pretreatment allowed excellent recoveries for low molecular mass 
opioid peptides (>70%) [37]. Furthermore, LODs were improved by C18-SPE-CE-MS 
between 1000 and 10000 times compared to CE-MS, depending on the peptides and the 
sample [39]. Figure 2 shows the total ion electropherograms (TIEs) obtained for the 
mice plasma samples by C18-SPE-CE-MS. As can be observed, separation resolution is 
not high because of the complexity of the sample. All the electropherograms present a 
characteristic profile with two time regions with the most intense peaks (approximately 
at 10-25 min and 30-40 min, respectively), and advanced chemometrics methods are 
necessary for high throughput and reliable comparison between the different sets of 
plasma samples.  
 
3.2 MCR-ALS analysis and detection of the most relevant metabolites 
 
MCR-ALS was applied using a column-wise augmented data matrix containing 
simultaneously the information of the 15 samples (wt and HD, both at 8, 12 and 30 
weeks) and allowed the resolution of the electropherogram profiles and corresponding 
mass spectra of the plasma metabolites. 
 
MCR-ALS analysis was performed separately on column-wise augmented data matrices 
of different m/z ranges (at the resolution of 0.01 Da/e), corresponding to the two 
selected time windows. A total number of 60 column-wise augmented matrices (two 
time windows x 30 m/z intervals) were separately analysed. The number of components 
selected was related to the number of electrophoretic peaks, despite the fact that some of 
these resolved components could be due to contributions such as solvent background or 
instrumental noise. In most of the cases, MCR-ALS models showed an explained 
variance (R2) of almost 100%. The electropherogram profiles for the resolved MCR-
ALS components in the six sample sets (i.e. 8wt, 12wt, 30wt and 8HD, 12HD and 
30HD) were compared and only resolved components of Caug that showed S/N ratios 
higher than 10% of the abundance of the most intense component were finally selected 
(in order to remove contributions such as solvent background or instrumental noise). 
The mass spectra of these components (from ST) were used to identify the m/z values 
causing the discrimination between samples. After the resolution and analysis of the 60 
augmented data matrices, a total number of 74 features were detected. Finally, peak 
areas of these candidate m/z values were recovered from the full scan raw C18-SPE-CE-
MS data using the MassHunter workstation software, taking as a reference the m/z 
value and the migration time of features obtained from the MCR-ALS resolved 
components. 
 
PLS-DA was then applied to identify the most important metabolites responsible for the 
sample discrimination considering the raw peak areas for the selected 74 candidate 
metabolites. In order to identify potential Huntington biomarkers which could be useful 
to discriminate between wt and HD samples, as well as to follow-up the HD 
progression, three different PLS-DA models were built. Figure 3 shows the PLS-DA 
scores plot for the mice plasma samples taking into account the three mentioned 
models. As can be observed in Figure 3A, the first PLS-DA model was applied to 
discriminate between control and HD samples. This model permitted us to propose 
possible biomarkers involved in HD. Two latent variables (LVs) explained 34% and 
89% of the X and Y variances, respectively. The second PLS-DA model was applied to 
differentiate between wt samples of different ages and identify metabolites involved in 
aging of healthy controls. In order to improve the reliability of the PLS-DA model due 
to the limited amount of samples, a two-class model was used, which presented at least 
3 samples in each class (8 weeks and 12-30 weeks). These two sets of samples were 
also the best option to differentiate later between aging and early HD progression. A 
PLS-DA model with two latent variables (LVs) explained 47% of the X-variance and 
the 99% of the Y-variance (Figure 3B). Finally, the third PLS-DA model was applied to 
distinguish between HD samples of different ages and identify possible biomarkers 
which could be useful to follow-up the disease progression. Again, the same two sets of 
samples were defined (8 weeks and 12-30 weeks). In this case, two latent variables 
(LVs) explained 52% and 98% of the X and Y variances, respectively (see Figure 3C). 
All PLS-DA models allowed class discrimination and the detection of the most relevant 
components for the differentiation of the samples. It is worth mentioning that HD 
samples of 12 and 30 weeks were slightly separated in the scores plot (Figure 3C), 
whereas this separation was not observed for wt samples (Figure 3B). Anyway, a 3 class 
PLS-DA model was not recommended because of the limited amount of samples. VIP 
scores values higher than 1 were used as a feature selection tool in order to choose only 
the most relevant candidate metabolites for each PLS-DA model (33 out of 74).  
 
3.3. Tentative metabolite identification and biological meaning 
 
The most contributing metabolites to sample discrimination (33) were tentatively 
identified, taking advantage of the highly accurate experimental molecular mass values 
provided by the oa-TOF mass spectrometer. Only 29 features of the total of 33 were 
tentatively identified with an error lower or equal to 20 ppm (Table 1) (the 4 non-
identified features were discarded for further discussion). As can be observed in Table 
1, there were some ambiguities on the metabolite identities because this tentative 
identification was solely based on the agreement between the experimental and the 
theoretical molecular mass values. For example, in some cases several isobaric 
metabolites were proposed for a certain molecular formula and experimental molecular 
mass value (i.e. ID 2, 3, 4, 6, 7, 9, 13, 15, 16, 17, 18, 19, 29). In other cases, it was not 
possible to differentiate between metabolites with very close theoretical molecular mass 
values because Er≤ 20 ppm (i.e. ID 6 (Er=7 and 14 ppm), ID 8 (Er=16 and 18 ppm), ID 9 
(Er=2 and 15 ppm), ID 10 (Er=13 and 17 ppm), and ID 25 (Er=7 and 16 ppm)). In the 
future, analysis of standard samples and MS/MS measurements for structure 
characterisation would be necessary to improve reliability of these identity assignments.  
The Venn diagrams that appear as insets in Figures 4A and 4B show the relations 
between the identified metabolites that explain HD progression and aging of healthy 
controls. As can be observed, 7 metabolites (4+3) were useful to specifically explain 
HD progression (HD set, ID 1, 10, 28, 3, 13, 15 and 24 in Table 1 and Figure 4). 
Similarly, 8 metabolites (8+0, ID 5, 6, 14, 16, 20, 21, 22 and 23 in Table 1 and Figure 4) 
were useful to specifically explain aging of healthy controls (wt set). The concentration 
trends of these specific metabolites were varied (Figures 4A and 4B), some of them 
decrease, while others increase after 12 weeks of birth. Finally, there were 8 metabolites 
(7+1, ID 29, 4, 11, 26, 7, 8, 9 and 19 in Table 1 and Figure 4) that were explaining both 
progression of HD and aging. 4 of them showed a clear different concentration trend in 
HD and wt plasma samples, but for the other 4 metabolites the trend was similar, 
indicating that differences were found on their absolute concentration (e.g., ID 8 
normalised areas in HD and wt plasma samples were 466.4072 and 431.2187, 
respectively). With regard to differentiation in general of wt and HD samples (wt/HD 
set), there were 6 metabolites that were useful to specifically distinguish between 
control and HD samples, 4 downregulated and 2 upregulated in HD samples, as shown 
in Figure 4C (ID 2, 12, 18, 25, 17 and 27 in Table 1). For metabolites explaining also 
HD progression and/or aging (ID 10, 15, 1 and 11 in Table 1 and Figure 4C), the 
concentration trends were varied (2 were downregulated and 2 upregulated).    
 
The identified metabolites were searched against different on-line databases to identify 
the potential metabolic pathways that could be involved in HD pathology. Different 
metabolic pathways were found to be related to 13 of the 29 identified metabolites (see 
Table 2). It is well-known that HD could affect different metabolic pathways. 
Huntingtin is ubiquitously expressed and, in addition to neurological features, the 
peripheral phenotype of HD could include weight loss, energy disturbances and 
alteration of endocrine function.  
 
As it is shown in Figure 4A, concentrations of phenylalanyl-arginine and arginyl-
phenylalanine (ID 13, Table 1) were found increased in HD mice after 12 weeks of birth 
(Figure 4A). These metabolites, which were specific to explain HD progression, are 
incomplete breakdown products of protein digestion or protein catabolism known to 
have physiological or cell-signalling effects (Table 2) [53]. Similarly, prostaglandins, 
thromboxanes, lipoxins and leukotrienes (ID 15, Table 1) were found upregulated after 
12 weeks (Figure 4A), but downregulated when all HD samples were compared to all 
controls (Figure 4C), thus indicating a change of trend after 12 weeks. These 
metabolites are related with regulation of inflammatory processes and signalling 
pathways, mainly the arachidonic acid metabolism, the neuroactive ligand-receptor 
interaction, the serotonergic synapse, the cAMP signalling pathway and the oxytocin 
signalling pathway (see Table 2). The arachidonic acid metabolism has been also related 
with the synthesis of cytochromes involved in the mitochondrial oxidative 
phosphorylation, and altered mitochondrial function has been associated to HD [54,55]. 
Furthermore, cAMP levels have been found reduced in the striatum of several HD 
mouse models [56], while the oxytocin signalling pathway has been related with 
changes in the hypothalamic and limbic systems that take place at HD early stages [57]. 
Concentration of L-urobilinogen (ID 24, Table 1), which is related with the porphyrin 
metabolism (Table 2), was also found increased after 12 weeks of birth (Figure 4A). All 
these changes in 12 weeks-old HD mice suggest an onset on specific neuronal 
dysfunction, altered expression of several types of receptors and changed expression of 
neurotransmitters and key proteins. Unbalanced activity within these pathways provides 
a potential mechanism for many of the pathological phenotypes associated with HD, 
such us transcriptional dysregulation, inflammation and ultimately neurodegeneration 
[58–60]. 
 With regard to metabolites explaining both progression of HD and aging (Figure 4A and 
4B), gangliosides (ID 29, Table 1), which are cell plasma membrane components that 
modulate cell signal transduction events, showed a different concentration trend on HD 
progression compared to aging. Gangliosides levels decreased after 12 weeks of birth in 
HD progression (Figure 4A), while increased in controls (Figure 4 B). Decreased 
ganglioside concentration has been also found in the cerebellum of R6/1 (HD) mice at 
35-40 weeks [61], and in fibroblasts, cortex and striatum of YAC128 mice [62]. 
Similarly, L-hexanoylcarnitine levels (ID 11, Table 1), which decreased with aging in 
healthy controls (Figure 4B), were found to increase with HD progression (Figure 4A), 
and also when all HD samples were compared to all controls (Figure 4C), suggesting 
that the disease involves disturbances in energy production, which are characterised by 
production and excretion of unusual acylcarnitines [63]. Concentration of 
PC(14:1(9Z)/14:1(9Z)) (ID 26, Table 1), which is related with signalling pathways (the 
arachidonic acid metabolism and the retrograde endocannabinoid signalling), the 
glycerophospholipid metabolism and the linoleic acid metabolism, was also found 
increased with HD progression and decreased with wt aging (Table 2, Figure 4A and 
4B). In contrast, changes on the concentration trend with HD progression or aging of (-
)-epinephrine and normetanephrine (ID 7, Table 1), which are metabolites related with 
tyrosine metabolism and signalling pathways (cAMP signalling pathway, adrenergic 
signalling in cardiomyocytes and neuroactive ligand-receptor interaction) (Table 2) 
were not observed (Figure 4A and 4B). These metabolites were found decreased after 
12 weeks in HD progression and aging (Figure 4A and 4B). The same trend was 
observed for vanylglycol and phosphorylcholine (ID 8, Table 1, Figures 4A and 4B), 
which are related with the tyrosine and the glycerophospholipid metabolisms, 
respectively (Table 2). Finally, metabolites with ID 9 (Table 1), presented again a 
decreasing trend in both HD progression and wt aging (Figures 4A and 4B). In this case, 
3-indolebutyric acid is related with the tryptophan metabolism, while the other 
metabolites are incomplete products of protein digestion or protein catabolism 
associated with cell signalling effects (Table 2) [64].  
 
With regard to metabolites explaining only wt aging, dimethylbenzimidazole (ID 5, 
Table 1), which is related with the riboflavin and porphyrin metabolisms (Table 2), was 
found reduced after 12 weeks of birth (Figure 4B). The same concentration trend was 
observed for 18-hydroxycorticosterone and cortisol (ID 16, Table 1, Figure 4B), which 
are metabolites associated with the steroid hormone biosynthesis (Table 2).  
 
Comparing all HD samples with all controls, concentration levels of m-cresol and p-
cresol (ID 2, Table 1), which are involved in protein digestion and absorption, as well as 
in degradation of aromatic compounds, were found downregulated in HD samples 
(Figure 4C). The same concentration trend was observed for histidinyl-histidine (ID 12, 
Table 1, Figure 4C), an incomplete breakdown product of protein digestion or 
catabolism with cell signalling effects [65,66]. 
 
4. Concluding remarks 
 
An optimised sample pretreatment was applied to wild type and R6/1 mice plasma 
samples (of 8, 12 and 30 weeks) prior to the analysis by C18-SPE-CE-MS. The proposed 
methodology demonstrated to be suitable to ensure a reliable and comprehensive 
metabolite profiling of the plasma samples. The combination of MCR-ALS with other 
chemometric tools, such as PLS-DA, allowed the comprehensive analysis of the C18-
SPE-CE-MS metabolomic data, resolving electrophoretic peaks and mass spectra of a 
large number of metabolites. Finally, a list of potential metabolites useful to 
discriminate between control and HD plasma samples, as well as to follow-up the HD 
progression, were tentatively identified, and the most affected metabolic pathways were 
discussed. Although different pathways were found altered in HD, the intracellular 
signalling was observed to be the most affected, especially after 12 weeks of birth, thus 
suggesting that the pathology involves dysfunction of specific neurons, altered 
expression of several types of receptors and changed expression of neuro-transmitters. 
In addition, although some of the identified metabolites have been previously described 
in the striatum of R6/1 (HD) mice or other rat models, attempts to find such biomarkers 
in plasma have hitherto been unsuccessful. In the present work, we propose direct brain-
striatal metabolites as good biomarkers that can be found in periphery (plasma samples). 
Therefore, we provide a window of opportunity for prediction of disease onset, 
evaluation of HD early progression or response to treatment.  
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Figure legends 
 
Figure 1. Workflow of C18-SPE-CE-MS data analysis: (A) Pre-processing of data set, 
(B) data arrangement and MCR-ALS analysis in order to detect metabolites, and (C) 
tentative identification of relevant metabolites and metabolic pathways. 
 
Figure 2. Total ion electropherograms (TIEs) obtained by C18-SPE-CE-MS for (i) wt 
and (ii) HD plasma samples at (A) 8, (B) 12 and (C) 30 weeks. 
 
Figure 3. PLS-DA scores plot for the mice samples in order to differentiate between 
(A) all wt and HD plasma samples, (B) wt samples at 8, and from 12 to 30 weeks, and 
(C) HD samples at 8, and from 12 to 30 weeks. Every sample was analysed in triplicate 
(with the exception of 12wt, 12HD and 30HD, for which only two replicates were 
analysed due to the small volume of plasma sample provided). 
 
Figure 4. Bar graphs with the folding trends for the identified metabolites (Table 1) that 
were used to explain (A) HD progression (set HD), (B) aging of healthy controls (set 
wt) and (C) differences between wt and HD plasma samples (set wt/HD). The % of 
Abundance of each metabolite was calculated normalising to the metabolite presenting 
the highest abundance. (*See Table 2 for the related metabolic pathways). 
   
   
   
  
 
  
 
